Alphatec vs. Inspire Medical Systems: Which Healthcare Stock Is a Better Buy in 2026?
Written by Sara Appino for The Motley Fool -> Alphatec focuses on a comprehensive spine surgery ecosystem to capture market share through integrated imaging and surgical solutions. Inspire Medical Systems dominates the sleep apnea neurostimulation market with a profitable, high
Alphatec focuses on a comprehensive spine surgery ecosystem to capture market share through integrated imaging and surgical solutions.
Inspire Medical Systems dominates the sleep apnea neurostimulation market with a profitable, high-growth business model.
Which medical technology innovator deserves a place in your long-term investment portfolio?
Deciding between high-growth healthcare players often involves choosing between specialized surgical tools and innovative patient therapies. Both Alphatec (NASDAQ:ATEC) and Inspire Medical Systems (NYSE:INSP) offer compelling opportunities for investors seeking medical device exposure.
Alphatec specializes in a full-stack approach to spine surgery, integrating imaging and surgical technology to improve clinical outcomes. Inspire focuses on neurostimulation for obstructive sleep apnea, offering an alternative to traditional breathing machines. While both operate in the medical technology field, their financial profiles and market maturity levels provide different entry points for retail investors.
Alphatec operates as a spine-focused technology provider, developing advanced hardware and software solutions for complex surgical procedures. It differentiates itself through an integrated ecosystem, utilizing subsidiaries like EOS imaging and SafeOp Surgical to support surgeons through the entire clinical workflow. The company primarily serves the U.S. hospital market but is actively expanding its international footprint in Europe and Japan to reach a broader patient base.
In FY 2025, revenue reached nearly $764.2 million, representing a significant 25.0% increase over the prior year as adoption of its spine solutions grew. Despite this top-line momentum, the company reported a net loss of approximately $143.4 million for the period. The net margin, which measures the percentage of revenue remaining after all expenses, improved to negative 18.8% from negative 26.5% during the previous fiscal year.
As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 17.2x, meaning total debt is much higher than shareholder equity. The current ratio, which measures the ability to pay short-term debts with short-term assets, is approximately 2.1x. Note that stock-based compensation represented roughly 163.0% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.
